These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37190184)

  • 21. Does concomitant ductal carcinoma in situ affect the clinical outcome in breast cancer patients with invasive ductal carcinoma: An Asian perspective.
    Lee WP; Shetty SS; Seah CMJ; Tan PT; Tan SM
    Cancer Rep (Hoboken); 2022 Sep; 5(9):e1646. PubMed ID: 35892151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathological characteristics and prognosis of triple-negative breast cancer invasive ductal carcinoma with ductal carcinoma in situ.
    Liu Y; Yu T
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11181-11191. PubMed ID: 37354223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different distribution of breast ductal carcinoma in situ, ductal carcinoma in situ with microinvasion, and invasion breast cancer.
    Zhang W; Gao EL; Zhou YL; Zhai Q; Zou ZY; Guo GL; Chen GR; Zheng HM; Huang GL; Zhang XH
    World J Surg Oncol; 2012 Dec; 10():262. PubMed ID: 23216911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraductal carcinoma (ductal carcinoma in situ) of the breast. A comparison of pure noninvasive tumors with those including different proportions of infiltrating carcinoma.
    Moriya T; Silverberg SG
    Cancer; 1994 Dec; 74(11):2972-8. PubMed ID: 7954261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of ductal carcinoma in situ on the outcome of invasive breast cancer. A prospective cohort study.
    Lopez Gordo S; Blanch Falp J; Lopez-Gordo E; Just Roig E; Encinas Mendez J; Seco Calvo J
    Int J Surg; 2019 Mar; 63():98-106. PubMed ID: 30738200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frankly Invasive Carcinoma Ex-intraductal Carcinoma: Expanding on an Emerging and Perplexing Concept in Salivary Gland Tumor Pathology.
    McLean-Holden AC; Rooper LM; Lubin DJ; Magliocca KR; Manucha V; Sadow PM; Tobias J; Vargo RJ; Thompson LDR; Heidarian A; Weinreb I; Wenig B; Gagan J; Hernandez-Prera JC; Bishop JA
    Head Neck Pathol; 2022 Sep; 16(3):657-669. PubMed ID: 34985683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma
    Guo Q; Li VZ; Nichol JN; Huang F; Yang W; Preston SEJ; Talat Z; Lefrère H; Yu H; Zhang G; Basik M; Gonçalves C; Zhan Y; Plourde D; Su J; Torres J; Marques M; Habyan SA; Bijian K; Amant F; Witcher M; Behbod F; McCaffrey L; Alaoui-Jamali M; Giannakopoulos NV; Brackstone M; Postovit LM; Del Rincón SV; Miller WH
    Cancer Res; 2019 Apr; 79(7):1646-1657. PubMed ID: 30659022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic Alterations during the
    Trinh A; Gil Del Alcazar CR; Shukla SA; Chin K; Chang YH; Thibault G; Eng J; Jovanović B; Aldaz CM; Park SY; Jeong J; Wu C; Gray J; Polyak K
    Mol Cancer Res; 2021 Apr; 19(4):623-635. PubMed ID: 33443130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study.
    Iakovlev VV; Arneson NC; Wong V; Wang C; Leung S; Iakovleva G; Warren K; Pintilie M; Done SJ
    Clin Cancer Res; 2008 Jul; 14(14):4446-54. PubMed ID: 18628458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain.
    Werling RW; Hwang H; Yaziji H; Gown AM
    Am J Surg Pathol; 2003 Jan; 27(1):82-90. PubMed ID: 12502930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of heterozygosity analyses of asynchronous lesions of ductal carcinoma in situ and invasive ductal carcinoma of the human breast.
    Amari M; Moriya T; Ishida T; Harada Y; Ohnuki K; Takeda M; Sasano H; Horii A; Ohuchi N
    Jpn J Clin Oncol; 2003 Nov; 33(11):556-62. PubMed ID: 14711979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of maspin is up-regulated during the progression of mammary ductal carcinoma.
    Umekita Y; Yoshida H
    Histopathology; 2003 Jun; 42(6):541-5. PubMed ID: 12786889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival.
    Dieterich M; Hartwig F; Stubert J; Klöcking S; Kundt G; Stengel B; Reimer T; Gerber B
    Breast; 2014 Aug; 23(4):346-51. PubMed ID: 24559611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Grade of ductal carcinoma in situ accompanying infiltrating ductal carcinoma as an independent prognostic factor.
    Kim JY; Han W; Moon HG; Park IA; Ahn SK; Kim J; Lee JW; Kim T; Kim MK; Noh DY
    Clin Breast Cancer; 2013 Oct; 13(5):385-91. PubMed ID: 23870857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p53 nuclear accumulation and ERalpha expression in ductal hyperplasia of breast in a cohort of 215 Chinese women.
    Mao XY; Fan CF; Zheng HC; Wei J; Yao F; Jin F
    J Exp Clin Cancer Res; 2010 Aug; 29(1):112. PubMed ID: 20712900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breast cancer risk factor associations differ for pure versus invasive carcinoma with an in situ component in case-control and case-case analyses.
    Ruszczyk M; Zirpoli G; Kumar S; Bandera EV; Bovbjerg DH; Jandorf L; Khoury T; Hwang H; Ciupak G; Pawlish K; Schedin P; Masso-Welch P; Ambrosone CB; Hong CC
    Cancer Causes Control; 2016 Feb; 27(2):183-98. PubMed ID: 26621543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extensive ductal carcinoma In situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH.
    Aubele M; Mattis A; Zitzelsberger H; Walch A; Kremer M; Welzl G; Höfler H; Werner M
    Int J Cancer; 2000 Jan; 85(1):82-6. PubMed ID: 10585588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibin/activin subunits (inhibin-alpha, -betaA and -betaB) are differentially expressed in human breast cancer and their metastasis.
    Mylonas I; Jeschke U; Shabani N; Kuhn C; Friese K; Gerber B
    Oncol Rep; 2005 Jan; 13(1):81-8. PubMed ID: 15583806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic pathways in the evolution of breast ductal carcinoma in situ.
    Farabegoli F; Champeme MH; Bieche I; Santini D; Ceccarelli C; Derenzini M; Lidereau R
    J Pathol; 2002 Mar; 196(3):280-6. PubMed ID: 11857490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.